Overview
- Federal data show thousands of Candida auris detections this year, with CDC counts reporting roughly 3,130 screening detections and about 3,302 clinical infections through the week ending July 18.
- The fungus mainly spreads in hospitals and nursing homes by colonized patients and contaminated surfaces, and it can persist on equipment for weeks before causing illness.
- CDC testing of 2022–23 samples found over 95% of isolates resistant to fluconazole, 15% resistant to amphotericin B, about 1% resistant to echinocandins, and under 1% resistant to all three major drug classes.
- State totals vary by the metric used because screening counts track colonization while clinical counts record confirmed infections, producing different leaders such as Texas and Michigan on screening lists and California prominent in clinical tallies.
- Public‑health actions focus on rapid detection, expanded lab capacity and targeted screening, strict isolation and use of EPA‑approved disinfectants, and reliance on echinocandins when effective as officials warn about the threat of multidrug and rare pan‑resistant strains.